FBRX
Forte Biosciences Inc
NASDAQ: FBRX · HEALTHCARE · BIOTECHNOLOGY
$28.03
+6.23% today
Updated 2026-04-29
Market cap
$537.90M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.71
Dividend yield
—
52W range
$6 – $36
Volume
0.3M
Forte Biosciences Inc (FBRX) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $62.17M | $35.35M | $92.07M | $103.08M | $7.66M | $61.24M | $43.31M | $42.00M | $38.98M | $61.56M |
| Cash & equivalents | $8.15M | $5.51M | $35.93M | $40.81M | $6.94M | $58.77M | $42.04M | $41.10M | $11.96M | $22.24M |
| Current assets | $60.20M | $32.46M | $90.63M | $97.75M | $7.51M | $59.90M | $42.52M | $41.51M | $38.33M | $61.35M |
| Total liabilities | $23.09M | $28.36M | $20.99M | $44.94M | $1.91M | $2.26M | $1.76M | $3.18M | $3.67M | $9.08M |
| Current liabilities | $5.93M | $14.38M | $17.33M | $16.53M | $1.91M | $2.26M | $1.76M | $3.18M | $3.67M | $9.08M |
| Long-term debt | $17.05M | $13.77M | $3.63M | $26.20M | — | — | — | — | — | — |
| Shareholder equity | $39.08M | $7.00M | $71.08M | $58.15M | $5.75M | $58.98M | $41.55M | $38.82M | $35.31M | $52.48M |
| Retained earnings | $-94.51M | $-128.00M | $-166.93M | $-215.88M | $-4.97M | $-51.46M | $-73.17M | $-87.04M | $-118.52M | $-154.00M |
| Accounts receivable | — | — | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — |